10-Q: Inhibitor Therapeutics Reports Q3 Loss, Cash Dwindles

Inhibitor Therapeutics, Inc. reported an increased nine-month net loss and a significant decline in cash reserves, signaling potential future capital needs despite progress in drug development.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $2,004,972, compared to $1,917,358 for the same period in 2024.
• Cash and cash equivalents significantly decreased to $2,976,658 as of September 30, 2025, from $5,606,863 at December 31, 2024.
• Total stockholders' equity plummeted to $3,453 as of September 30, 2025, from $1,985,040 at December 31, 2024.
• Research and development expenses for the nine months ended September 30, 2025, were $939,470, an increase from $869,756 in the prior year period.
• General and administrative expenses decreased to $1,172,069 for the nine months ended September 30, 2025, from $1,303,404 in the prior year, primarily due to reduced compensation costs.
• The company is pursuing FDA approval for its itraconazole formulation for Basal Cell Carcinoma Nevus Syndrome (BCCNS) and expects to submit a New Drug Application (NDA) without requiring additional clinical trials, pending a pharmacokinetic (PK) crossover study.
• A new 2025 Equity Incentive Plan, authorizing 20 million shares, was approved by the Board of Directors in October 2025, subject to shareholder approval.
• The company entered into a performance-based master services agreement with Frameshift Management, Inc. in October 2025 for consulting services, with compensation including warrants vesting upon specific program milestones.

Sentiment

Score: 2

Explanation: The company's financial position has significantly deteriorated with a substantial decrease in cash and equity, and an increased cash burn. While there is ongoing progress in drug development, the short financial runway and explicit mention of uncertain future capital raises present a high level of risk and negative sentiment.

Positives

• General and administrative expenses decreased for both the three-month and nine-month periods ended September 30, 2025, primarily due to a reduction in compensation costs.
• Net loss for the three months ended September 30, 2025, slightly improved to $(712,184) compared to $(730,957) in the prior year period.
• Progress has been made in the FDA pre-IND process for itraconazole in BCCNS, with a novel formulation developed by Avior Bio and a PK crossover study planned to support an NDA without further clinical trials.
• The company has submitted an application to participate in the FDA's Rare Disease Endpoint Advancement (RDEA) pilot program.
• No current pending legal proceedings are affecting the company.

Negatives

• Cash and cash equivalents decreased significantly by $2,630,205 during the nine months ended September 30, 2025, ending the period with $2,976,658.
• Total stockholders' equity declined substantially from $1,985,040 at December 31, 2024, to $3,453 at September 30, 2025.
• The accumulated deficit increased to $(54,124,229) as of September 30, 2025, from $(52,119,257) at December 31, 2024.
• Net cash used in operating activities increased to $(2,630,205) for the nine months ended September 30, 2025, from $(2,461,608) in the prior year period, indicating an accelerated cash burn.
• Interest income decreased significantly for both the three-month and nine-month periods due to less deposits in money market accounts.
• The company explicitly states there can be no assurances of success in raising additional capital on economically reasonable terms, if at all, which is a significant going concern risk.

Risks

• Investing in common stock is highly speculative and involves a high degree of risk.
• Ability to develop and ultimately commercialize therapeutics is uncertain.
• Results from discussions with the FDA may not be favorable or timely.
• Application and availability of corporate funds and the need for future funds are critical.
• Acceptance of the business model by investors and potential commercial collaborators is not guaranteed.
• Future capital requirements and the ability to satisfy capital needs are uncertain.
• Ability to commence and complete required clinical trials and obtain FDA or other regulatory approvals is a significant challenge.
• Ability to secure and maintain key development and commercialization partners for product candidates is not assured.
• Ability to obtain, maintain, or protect the validity of owned or licensed patents and other intellectual property is crucial.
• Ability to internally develop, acquire, or license new inventions and intellectual property is essential for growth.
• Ability to retain key executive members is vital for operational continuity.
• Interpretations of current laws and the passage of future laws, rules, and regulations applicable to the business could negatively impact operations.
• Impact of U.S. government shutdowns and funding shortages at governmental and regulatory agencies (FDA, SEC) could hinder regulatory reviews and access to capital markets.

Future Outlook

The company expects to have sufficient cash for the foreseeable future to manage its business and pursue the FDA process for the BCCNS product without further clinical trials. Upon clarification of BCCNS NDA requirements within the next six months, the company will assess capital requirements for additional opportunities, potentially raising capital through equity or debt, though success is not assured.

Management Comments

• Management believes all adjustments necessary to present fairly the financial position, results of operations, and cash flows have been made.
• Management expects research and development expenses to continue to increase in the future, depending on the results from upcoming FDA meetings.
• Certifying Officers concluded that disclosure controls and procedures were effective as of the end of the period.
• No material changes in internal control over financial reporting occurred during the third fiscal quarter of 2025.

Industry Context

Inhibitor Therapeutics operates in the pharmaceutical development sector, specifically focusing on drug repurposing for oncology and proliferation disorders. The strategy of utilizing already approved active pharmaceuticals like itraconazole aims to reduce development timelines and costs compared to novel drug discovery. Participation in programs like the FDA's Rare Disease Endpoint Advancement (RDEA) pilot program indicates a focus on niche markets with high unmet needs, which can offer expedited regulatory pathways and market exclusivity. The reliance on a single primary drug candidate (itraconazole) and the need for FDA approval for a novel formulation places the company's future heavily on regulatory success and the outcome of its PK crossover study.

Comparison to Industry Standards

• The company's strategy of repurposing an already FDA-approved drug (itraconazole) for new indications (BCCNS, prostate, lung cancers) is a common approach in the biotech industry, often pursued by smaller companies to mitigate the high costs and risks associated with de novo drug discovery. This approach is exemplified by companies like Jazz Pharmaceuticals (Xyrem, repurposed for narcolepsy) or Horizon Therapeutics (Krystexxa, repurposed for chronic refractory gout).
• The engagement of external experts and Avior Bio for formulation development and PK studies aligns with industry best practices for specialized drug development, particularly for optimizing drug delivery and demonstrating bioequivalence or bioavailability for regulatory submissions.
• The significant cash burn and dwindling cash reserves, with an accumulated deficit exceeding $54 million, are typical for early-stage pharmaceutical development companies that are pre-revenue. However, a cash balance of under $3 million with ongoing R&D and G&A expenses suggests a short cash runway, which is below the comfort level for many industry peers who often maintain at least 12-18 months of operating capital.
• The reliance on a single asset (itraconazole for BCCNS) for near-term value creation is a common characteristic of small biotechs, but it also concentrates risk. Larger pharmaceutical companies typically have diversified pipelines to offset individual asset failures.

Corporate Governance

Legal Proceedings

• The company is not currently the subject of any pending legal proceedings.

Related Party Transactions

• The company engaged Avior Bio, Inc. for the development of a novel formulation of itraconazole. Niraj Vasisht, President and Chairman of Avior, is a member of the company's Board of Directors.
• Costs incurred with Avior Bio were $0.2 million for the nine months ended September 30, 2025, compared to $0.1 million for the same period in 2024.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and the newly approved 2025 Equity Incentive Plan. The substantial decline in equity and cash reserves indicates increased financial risk.
• **Employees**: The 2025 Equity Incentive Plan offers potential for stock-based compensation, which could aid in retention and motivation.
• **Creditors**: The company's deteriorating financial position and reliance on future capital raises may increase perceived credit risk.
• **Customers (future)**: Progress in drug development for BCCNS offers potential for a new therapeutic option, but regulatory hurdles remain.

Next Steps

• Conduct a pharmacokinetic (PK) crossover study of the novel itraconazole formulation and the formulation used in the HP2001 study.
• Prepare for a new pre-IND and New Drug Application (NDA) submission for the BCCNS product.
• Obtain clarification on the requirements for the BCCNS NDA within the next six months.
• Assess capital requirements necessary to pursue additional drug development opportunities.
• Seek shareholder approval for the 2025 Equity Incentive Plan within 12 months of Board approval.
• Continue to receive consulting services from Frameshift Management, Inc. for BCC programs.

Key Dates

Recommendation

The company's financial health has significantly deteriorated, marked by a substantial decline in cash and stockholders' equity, and an increased cash burn rate. While there is ongoing progress in drug development, the explicit mention of a need for future capital raises with no assurance of success creates considerable uncertainty and risk. The current financial runway appears short, making the stock highly speculative and vulnerable to further declines without successful financing. A seasoned investor would likely view the current financial position as unsustainable in the long term without significant external capital, warranting a 'sell' recommendation to mitigate further downside risk.

Keywords

Itraconazole, Basal Cell Carcinoma Nevus Syndrome, BCCNS, Prostate Cancer, Lung Cancer, Pharmaceutical Development, FDA Approval, Pre-IND Meeting, New Drug Application, NDA, Rare Disease Endpoint Advancement, RDEA, Johns Hopkins University, Avior Bio, Drug Repurposing, Oncology, Dermatology, Clinical Trials, Equity Incentive Plan, Cash Burn, Liquidity, Capital Raise